On October 14, 2025, Candel Therapeutics, Inc. secured a loan facility totaling up to $130 million, with an initial drawdown of $50 million; they also reported positive interim data for their CAN-3110 trial showing a median overall survival of 11.8 months in recurrent glioblastoma patients.